ResearcherChinese Academy of SciencesActive in the last 2 years

Simin Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6135-7546; OpenAlex author ID A5006887861. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 7

Papers, trials and grants by year

2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: 1 paper

Papers 2

Genome-wide CRISPR screens identify PKMYT1 as a therapeutic target in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s44321-024-00060-y ↗
Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression. Co-author DOI 10.1093/carcin/bgz086 ↗

Closest collaborators

The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Yuexiang Wang · 2 shared papers, 2020–2024 · strength 0.26
- Paper Genome-wide CRISPR screens identify PKMYT1 as a therapeutic target in pancreatic ductal adenocarcinoma. DOI 10.1038/s44321-024-00060-y ↗
- Paper Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression. DOI 10.1093/carcin/bgz086 ↗
Liwei Wang · 1 shared paper, 2024 · strength 0.16
- Paper Genome-wide CRISPR screens identify PKMYT1 as a therapeutic target in pancreatic ductal adenocarcinoma. DOI 10.1038/s44321-024-00060-y ↗
Xiaoqi Li · 1 shared paper, 2024 · strength 0.16
- Paper Genome-wide CRISPR screens identify PKMYT1 as a therapeutic target in pancreatic ductal adenocarcinoma. DOI 10.1038/s44321-024-00060-y ↗
Jiujie Cui · 1 shared paper, 2024 · strength 0.16
- Paper Genome-wide CRISPR screens identify PKMYT1 as a therapeutic target in pancreatic ductal adenocarcinoma. DOI 10.1038/s44321-024-00060-y ↗
Zhang Li · 1 shared paper, 2020 · strength 0.10
- Paper Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression. DOI 10.1093/carcin/bgz086 ↗
Ke Li · 1 shared paper, 2020 · strength 0.10
- Paper Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression. DOI 10.1093/carcin/bgz086 ↗
Chenghao Shao · 1 shared paper, 2020 · strength 0.10
- Paper Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression. DOI 10.1093/carcin/bgz086 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.